Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL; Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM.

PLoS One. 2012;7(3):e31334. doi: 10.1371/journal.pone.0031334. Epub 2012 Mar 14.

2.

Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).

Mitchell WM.

Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70. doi: 10.1586/17512433.2016.1172960. Review.

3.

A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome.

Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, et al.

Clin Infect Dis. 1994 Jan;18 Suppl 1:S88-95.

PMID:
8148460
4.

Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.

Smith ME, Haney E, McDonagh M, Pappas M, Daeges M, Wasson N, Fu R, Nelson HD.

Ann Intern Med. 2015 Jun 16;162(12):841-50. doi: 10.7326/M15-0114. Review.

5.

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.

Overton ET, Goepfert PA, Cunningham P, Carter WA, Horvath J, Young D, Strayer DR.

Vaccine. 2014 Sep 22;32(42):5490-5. doi: 10.1016/j.vaccine.2014.07.078. Epub 2014 Aug 13.

PMID:
25128802
6.

Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.

Castro-Marrero J, Sáez-Francàs N, Santillo D, Alegre J.

Br J Pharmacol. 2017 Mar;174(5):345-369. doi: 10.1111/bph.13702. Epub 2017 Feb 1. Review.

PMID:
28052319
7.

Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.

Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H, Mella O.

PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19.

8.

Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome.

Suhadolnik RJ, Reichenbach NL, Hitzges P, Adelson ME, Peterson DL, Cheney P, Salvato P, Thompson C, Loveless M, Müller WE, et al.

In Vivo. 1994 Jul-Aug;8(4):599-604.

PMID:
7893988
9.

Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial.

Sulheim D, Fagermoen E, Winger A, Andersen AM, Godang K, Müller F, Rowe PC, Saul JP, Skovlund E, Øie MG, Wyller VB.

JAMA Pediatr. 2014 Apr;168(4):351-60. doi: 10.1001/jamapediatrics.2013.4647.

PMID:
24493300
10.

Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial.

Roerink ME, Knoop H, Bredie SJ, Heijnen M, Joosten LA, Netea MG, Dinarello CA, van der Meer JW.

Trials. 2015 Oct 5;16:439. doi: 10.1186/s13063-015-0971-z.

11.

Mismatched double-stranded RNA: polyI:polyC12U.

[No authors listed]

Drugs R D. 2004;5(5):297-304.

PMID:
15357629
12.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
13.

Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme.

O'Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A.

Health Technol Assess. 2006 Oct;10(37):iii-iv, ix-x, 1-121.

14.

B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.

Fluge Ø, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, Kristoffersen EK, Sørland K, Bruland O, Dahl O, Mella O.

PLoS One. 2015 Jul 1;10(7):e0129898. doi: 10.1371/journal.pone.0129898. eCollection 2015.

15.

TLR3 agonists as immunotherapeutic agents.

Nicodemus CF, Berek JS.

Immunotherapy. 2010 Mar;2(2):137-40. doi: 10.2217/imt.10.8. Review. No abstract available.

16.

Human Placental Extract as a Subcutaneous Injection Is Effective in Chronic Fatigue Syndrome: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study.

Park SB, Kim KN, Sung E, Lee SY, Shin HC.

Biol Pharm Bull. 2016 May 1;39(5):674-9. doi: 10.1248/bpb.b15-00623. Epub 2016 Feb 25.

17.

Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.

Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA.

Ann Allergy Asthma Immunol. 1999 Feb;82(2):185-91.

PMID:
10071523
18.

A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.

McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G.

QJM. 2006 Jul;99(7):461-8. Epub 2006 Jun 29.

PMID:
16809351
19.

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.

Jasani B, Navabi H, Adams M.

Vaccine. 2009 May 26;27(25-26):3401-4. doi: 10.1016/j.vaccine.2009.01.071. Epub 2009 Feb 5.

PMID:
19200817
20.

A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.

Collatz A, Johnston SC, Staines DR, Marshall-Gradisnik SM.

Clin Ther. 2016 Jun;38(6):1263-1271.e9. doi: 10.1016/j.clinthera.2016.04.038. Epub 2016 May 24. Review.

PMID:
27229907

Supplemental Content

Support Center